Genotyping of BRCA1, BRCA2, p53, CDKN2A, MLH1 and MSH2 genes in a male patient with secondary breast cancer
Background. Some tumour suppressor genes (BRCA2) and mismatch repair genes (MSH2, MLH1) are correlated with an increased risk for male breast cancer.
Case report. Our patient developed secondary breast cancer after the treatment for Hodgkin's disease in childhood. DNA was isolated from the patients' blood and screened for mutations, polymorphisms and variants in BRCA1, BRCA2, p53, CDKN2A, MLH1 and MSH2 genes. We found no mutations but common polymorphisms, and three variants in mismatch repair genes.
Conclusions. Nucleotide variants c.2006-6T>C and p.G322D in MSH2 might be correlated with male breast cancer.
If the inline PDF is not rendering correctly, you can download the PDF file here.
Jazbec J Todorovski L Jereb B. Classification tree analysis of second neoplasms in survivors of childhood cancer. BMC Cancer 2007; 7: 1-6.
Metayer C Lynch CF Clarke EA Glimelius B Storm H Pukkala E et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000; 18: 2435-43.
Boussen H Kochbati L Besbes M Dhiab T Makhlouf R Jerbi G et al. [Male secondary breast cancer after treatment for Hodgkin's disease. Case report and review of the literature]. [French]. Cancer Radiother 2000; 4: 465-8.
Ozet A Yavuz AA Kömürcü S Oztürk B Safali M Arpaci F et al. Bilateral male breast cancer and prostate cancer: a case report. Jpn J Clin Oncol 2000; 30: 188-90.
Weiss JR Moysich KB Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 20-26.
Giordano SH Buzdar AU Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002; 137: 678-87.
Leinung S Horn LC Backe J. [Male breast cancer: history epidemiology genetic and histopathology]. [German]. Zentralbl Chir 2007; 132: 379-85.
Murata H Khattar NH Gu L Li GM. Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Cancer Lett 2005; 223: 143-50.
Latz D Alfrink M Nassar N Beyerle C. Breast cancer in a male patient after treatment of acute lymphoblastic leukemia including total body irradiation and bone marrow transplantation. Onkologie 2004; 27: 477-9.
Zebic-Sinkovec M Kadivec M Podobnik G Skof E Snoj M. Mammographycally occult high grade ductal carcinoma in situ (DCIS) as second primary breast cancer detected with MRI: a case report. Radiol Oncol 2010; 44: 228-31.
Thomas DB Rosenblatt K Jimenez LM McTiernan A Stalsberg H Stemhagen A et al. Ionizing radiation and breast cancer in men (United States). Cancer Causes and Control 1994; 5: 9-14.
Eeles RA. Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2000; 2: 283-90.
Malkin D. The role of p53 in human cancer. J Neurooncol 2001; 51: 231-43.
Zager V Cemazar M Hreljac I Lah TT Sersa G Filipic M. Development of human cell biosensor system for genotoxicity detection based on DNA damage-induced gene expression. Radiol Oncol 2010; 44: 42-51.
Cesar Paz-y-Mino Perez CJ Fiallo BF Leone PE. A polymorphism in the hMSH2 gene (gIVS12-6T>C) associated with non-Hodgkin lymphomas. Cancer Genet Cytogenet 2002; 133: 29-33.
Worrillow LJ Travis LB Smith AG Rollinson S Smith AJ Wild CP et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 2003; 9: 3012-20.
Ollila S Delmadi Bebek D Jiricny J Nystrom M. Mechanisms of pathogenicity in human MSH2 missense mutants. Human Mutation 2008: 29: 1355-63.